Add to ORKGincreases active metabolite exposure in women with reduced CYP2D6 metabo-lism: A multicenter study. J Clin Oncol 29:3232-3239, 2011 2. Rae JM: Personalized tamoxifen: What is the best way forward? J Cli
Background Disclosure of potential conflicts of interest (CoI) is a standard practice for many biome...
Disclosure of potential conflicts of interest (CoI) is a standard practice for many biomedical journ...
Tamoxifen is widely used in the treatment of breast cancer. It is a pro-drug metabolized to the more...
reaction. Oral anticancer agents such as gefitinib are gener-ally thought to be safer than other ant...
Context Disclosure of conflicts of interest (COIs) from pharmaceutical industry study funding and au...
of the symptoms following reduction of drug dosage confirmed the suspected diagnosis and agreed with...
2. Dufour A, Schneider F, Metzeler KH, et al: Acute myeloid leukemia with biallelic CEBPA gene mutat...
computed tomography-guided core needle biopsy on non-small cell lung cancers for epidermal growth fa...
authors declare no potential conflicts of interest. Acknowledgments: The authors would like to than...
drug utilization Conflicts of interest: No conflicts of interest were identified with regards to th...
Purpose: We sought to determine the prevalence, reliability, and predictors of conflict of interest ...
(IP) Intellectual property rights/inventor/patent holder; (SAB) Scientific advisory board Tamoxifen ...
Disclosure of Potential Conflicts of Interest J. Desai is a consultant/advisory board member for Gla...
Abstract CONTEXT: Disclosure of conflicts of interest (COIs) from pharmaceutical industry study fund...
1 Development of gene expression based score to predict sensitivity of multiple myeloma cells to DNA...
Background Disclosure of potential conflicts of interest (CoI) is a standard practice for many biome...
Disclosure of potential conflicts of interest (CoI) is a standard practice for many biomedical journ...
Tamoxifen is widely used in the treatment of breast cancer. It is a pro-drug metabolized to the more...
reaction. Oral anticancer agents such as gefitinib are gener-ally thought to be safer than other ant...
Context Disclosure of conflicts of interest (COIs) from pharmaceutical industry study funding and au...
of the symptoms following reduction of drug dosage confirmed the suspected diagnosis and agreed with...
2. Dufour A, Schneider F, Metzeler KH, et al: Acute myeloid leukemia with biallelic CEBPA gene mutat...
computed tomography-guided core needle biopsy on non-small cell lung cancers for epidermal growth fa...
authors declare no potential conflicts of interest. Acknowledgments: The authors would like to than...
drug utilization Conflicts of interest: No conflicts of interest were identified with regards to th...
Purpose: We sought to determine the prevalence, reliability, and predictors of conflict of interest ...
(IP) Intellectual property rights/inventor/patent holder; (SAB) Scientific advisory board Tamoxifen ...
Disclosure of Potential Conflicts of Interest J. Desai is a consultant/advisory board member for Gla...
Abstract CONTEXT: Disclosure of conflicts of interest (COIs) from pharmaceutical industry study fund...
1 Development of gene expression based score to predict sensitivity of multiple myeloma cells to DNA...
Background Disclosure of potential conflicts of interest (CoI) is a standard practice for many biome...
Disclosure of potential conflicts of interest (CoI) is a standard practice for many biomedical journ...
Tamoxifen is widely used in the treatment of breast cancer. It is a pro-drug metabolized to the more...